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ABSTRACT:
Background: increasing spread of drug resistance among Plasmodium falciparum 
poses a serious threat to malaria treatment. The situation is complicated not only 
because new drugs are expensive and slow in development but also because they 
must be effective, preferably have a novel method of action, with an acceptable 
level of adverse effects, and be deployed in such a way as to prolong their use.
Study Objectives: The study objective was to review and quantify the existing 
evidence that atovaquone plus proguanil for the treatment of Plasmodium 
falciparum malaria is a novel, safe, effective combination.
Methods: Literature search, screening, selection, extraction and met-analysis 
were employed in reaching the study objectives. The main outcome measures 
were the day 28 cure rates, mean fever and parasite clearance times. Also 
compliance and the incidence of adverse effects were assessed.
Results: using data from 5 pivotal randomised clinical trials; atovaquone proguanil 
was effective with a cure rate of 98.2% (373/380: 95%CI 96.2, 99.3). The mean 
fever and parasite clearance times were 32.8 hours (95% Cl 30.1, 35.4) and 64.1 
hours (95% Cl 62.3, 65.9) respectively. Response rate was 91.3% (380/416) with 
3.4% (14/416) withdrawals and 5.3% (22/414) loss to follow-up. The main adverse 
effects were abdominal pain (16.9%), vomiting (13.6%) and headache (12.1%)
Conclusion: Atovaquone-proguanil is effective and safe but currently expensive 
and potentially susceptible to resistance if deployed alone. It must therefore be 
reserved as a treatment alternative for patients who fail the existing malaria 
treatment, and must be protected by combining it with other antimalarials.
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1.0 INTRODUCTION:
1.1 BACKGROUND:
Malaria remains a major global public health problem. It is currently endemic in over 
one hundred countries, and an estimated 2400 million people constituting about forty 
percent of the world’s population live in areas at risk 12
The World Health Organisation (WHO) estimates that between 300-500 million clinical 
cases occur annually, resulting in over one million malaria deaths, each year: there are 
about 3,000 malaria deaths per day, world-wide, mostly in young children 
Malaria also imposes a huge socio-economic burden on families and governments in 
endemic areas through lost productivity and high health care costs 12.
The current resurgence of the disease is due in part to the rapid urbanisation and 
population growth, increased migration, dwindling financial and political support, and 
civil strife. In addition to deteriorating public health services and poor environmental 
practices, also mosquito vectors are developing resistance to commonly used 
insecticides, and the Plasmodium falciparum parasite is developing resistance to 
existing antimalarial drugs.
The increasing spread of drug-resistant Plasmodium falciparum, the predominant 
parasite of the four plasmodia species (P. falciparum, P. vivax, P. ovale and P. 
malariae) that cause malaria, is one of the greatest challenges currently facing most 
malaria control programmes worldwide 2 3 4.
Moreover, the disease is currently extending its incidence, as the epidemic is no 
longer a rural and focal disease. Malaria is now a serious health problem in many 
tropical urban centres where the vector, the anopheline mosquito, can find standing 
water to breed 5.
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Further the increase in endemic malaria has been accompanied by a significant 
increase in global travel, resulting in thousands of cases being transported to non­
endemic areas, a few giving rise to transmission by indigenous mosquitoes 6 7.
With currently no effective vaccine in sight and the malaria situation remaining difficult 
to manage, many millions of people are at risk. The major impact of the global malaria 
situation is, however, being felt in tropical and subtropical Asia, parts of south and 
Central America, and in Africa south of the Sahara, requiring special attention 2,e.
1.2 THE AFRICA MALARIA SITUATION:
Most of the world’s malaria cases occur in Africa. Of the 100 countries in the world 
that are considered malarious about half are in Africa south of the Sahara. Also 
over 90% of the worlds’ malaria deaths and about 80% of the annual worlds’ 
clinical cases occur in Africa 1 2.
Economically, it is a significant factor in lost productivity and opportunities for 
investment as it continues to be an impediment to tourism and foreign direct 
investment in Africa.
The estimated costs of malaria, in terms of strains on the health systems and 
economic activity lost are enormous. Malaria is estimated to account for about ten 
percent of the continents’ disease burden, about 40 percent of all outpatient visits 
and 3 out of 10 hospital admissions in most endemic areas.
In Africa, where malaria reaches a peak at harvest time and hits young adults 
especially hard, a single bout of the disease costs an estimated equivalent of 10 
working days. It is also estimated to costs rural households on average five to ten 
percent of the household income on treatment and prevention.
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Malaria costs sub-Saharan African economies over two billion United States
dollars annually, including costs for control and lost workdays: this is estimated to 
be 1-5% of gross domestic product and slow economic growth by about 1.3 
percent per year in endemic countries 2'8’9’10.
In Africa, people most at risk are the poor, the marginalized, pregnant women and 
young children. African children under five years of age are chronic victims of 
malaria; often suffering an average of up to six attacks a year.
Malaria is a major cause of impaired childhood development and absenteeism in 
schools across Africa south of the Sahara. The vast majority of cases and deaths 
occurring among young children in Africa are in remote areas with poor access to 
health services 2,6,1°-
The African situation is largely fuelled by the existence of suitable disease vectors 
and environments that are highly favourable for transmission, including poor socio­
economic development and the absence of adequate health systems to deliver 
control measures. In addition to these, are the poor public awareness, numerous 
conflicts and civil wars, population movements, rapid urbanisation and widespread 
P. falciparum chloroquine resistance 2 610
The malaria situation in Africa has been acute-on-chronic and is believed to be 
one of the major impediments to the continent’s human, material and 
socio-economic development.
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1.3 MALARIA CONTROL AND PREVENTION
Current efforts, strategies and approaches at malaria control and prevention have 
focussed on providing early diagnosis and prompt treatment, planning and 
implementing selective and sustainable preventive measures like personal 
protection and vector control, and to detect early, contain and prevent epidemics. 
In addition to the strengthening of local capacities in basic and applied research to 
permit and promote the regular assessments of the malaria situation, in particular 
the ecological, social and economic determinants of the disease, are receiving 
attention and emphasis 21112.
Despite these efforts, malaria has re-emerged and the control situation is 
worsening due to a variety of economic, environmental and clinical factors, notably 
the spread of drug resistance.
Malaria parasite resistance to the existing drugs is posing an increasing threat to 
successful malaria case management that plays a crucial role in control 
programmes. The once effective drug chloroquine is no longer useful in many 
areas. Also the effectiveness of amodiaqiune is declining due to drug resistance, 
as is that of sulfadoxime-pyrimethamine, especially in those countries that have 
adopted it as their first line drug. Many of the newer, efficacious, drugs tend to be 
unaffordable in poorer countries. The situation is very serious and is having a 
striking impact on childhood morbidity and mortality in most endemic areas.13,14,15
Urgent and novel strategies are needed to contain the malaria drug resistance 
situation in order to forestall the ongoing disaster, and though no satisfactory 
strategy has yet emerged. Combination treatment has been proposed in response 
to the situation.
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This study therefore reviewed the rationale for advocating the use of combination 
therapy for malaria treatment and the existing evidence that atovaquone plus 
proguanil is a novel, effective and safe combination.
The ultimate objective however, was to pool and quantify the available data 
concerning the clinical and parasitological efficacy and safety of the atovaquone 
plus proguanil combination for the treatment of acute Plasmodium falciparum 
malaria.
1.4 RATIONALE FOR MALARIA COMBINATION THERAPY:
The useful life span of any anti-microbial agent depends on how it is developed, 
deployed and used. These principles must therefore underline any measure to 
combat the spread of drug resistance. Measures currently proposed to deal with 
the malaria parasites resistance situation are; to ensure correct and effective 
treatment of acute malaria cases, to promote the rational use of anti-malarials, and 
to develop new antimalarials and the use of combination therapy.
Combination therapy is given priority for various reasons.
Firstly, the slowness and high cost of new drug development, is a problem, 
especially since malaria is predominantly a disease of the poor: hence new drug 
development is economically unattractive. In addition, there is limited capacity for 
research and drug development in endemic areas. Thirdly, it is extremely difficult 
to enforce rational and good drug use practices in endemic areas due to high 
illiteracy rates. Moreover in most of these areas there are often limited formal 
health facilities for malaria case management, access may be poor, and patients
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have to rely on informal suppliers: quality, dosages and efficacy of such drugs may 
be poor and may aggravate the spread of drug resistance.
What therefore appears feasible now is to deploy anti-malarials in such a way as 
to protect them and to prolong their useful life span, although no satisfactory 
strategy has yet been established. Combination malaria treatment defined as the 
use of two or more antimalarials with independent sites of action is currently seen 
as the best option 161719 Therefore prolonging drugs lifespan by combining them 
is a fundamental disease control strategy, at least in important diseases like 
malaria.
Drug resistance develops when spontaneously occurring parasite mutants with 
reduced susceptibility are selected and then transmitted. Drugs for which a single 
point mutation confers a marked reduction in susceptibility are particularly 
vulnerable. Low clearance and shallow concentration effect relationships increase 
the chance of selecting mutant strains 1617.
Therefore combining anti-malarial drugs that do not share the same resistance 
mechanisms would reduce the chance of selection. This is because the chance of 
a resistant mutant surviving is the product of the per parasite mutation rates for the 
individual drugs, multiplied by the number of parasites in an infection that are 
exposed to the drugs 161,17,19.
For example, if 1 in 10s parasites is resistant to drug A, and 1 in 108 is resistant to 
drug B, then 1 in 1014 will be simultaneously resistant to the drug A-drug B 
combination, so long as the two drugs have independent sites of action. Since 
most patients with malaria have between 108 and 1012 asexual parasites in the 
body, a doubly resistant parasite is predicted to be around 102° This high number
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of mutations needed to express total resistance will delay the development of 
resistance 16,17,19.
Combination treatment will also offer complete and rapid eradication of parasite 
load in symptomatic patients and thus reduces the chance of survival of resistant 
strains16, 1719. It will also improve cure rates and hence lower post-treatment 
transmission of the plasmodia gametocytes 18.
Moreover, this basic principle underlines the current treatment recommendations 
for tuberculosis, HIV/AIDS and many cancers. The use of these combinations has 
been effective, safe and accepted worldwide.
Again recent evidence from southeastern Asia suggests that malaria drug 
resistance has slowed down when combination therapy of the artemisinins and 
mefloquine was used to treat the multi-drug resistant Plasmodium falciparum 
malaria in that area 20,21.
What remains to be determined however is the optimum combination. Current 
strategies have been focussed mainly on the use of the artemisinin derivatives 
with either sulfadoxime-pyrimethamine or mefloquine. Nonetheless, sulfadoxime- 
pyrithamine and mefloquine are long acting drugs with long terminal half-lives, 
which make them a risk for resistance selection and renders their combinations 
short gap measures, although the search for optimum combinations and 
alternatives continues 19,20.
Atovaquone-proguanil is one combination with novel structures that has potential 
for new combination therapy. This combination is very effective, safe, short acting, 
synergistic and has a novel mechanism of action. In addition, it has been found in 
small studies in Africa and elsewhere to be extremely safe and efficacious.
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However, the individual evaluative studies have often been small in sample size 
and thus lack the necessary statistical power for adequate inference.
This review and meta-analysis therefore systematically reviews and quantifies the 
novelty, efficacy, safety or otherwise of the atovaquone plus proguanil combination 
for the treatment of Plasmodium falciparum malaria.
1.5 REVIEW OF ATOVAQUONE, PROGUANIL AND THEIR COMBINATION:
The emergence and spread of multi-drug resistant Plasmodium falciparum in most 
parts of the world has put at the forefront a compelling need to develop new 
antimalarials with novel structures that will be useful for limiting the morbidity and 
mortality of malaria infection. However to accomplish this, it is critical that 
compliance to the final therapy dosing must be high, and treatment regimens must 
be well tolerated and of relatively short duration. There is also a need to identify 
and include compounds that provide synergistic activity against the resistant strains 
with convenient regimes and acceptable safety profile. Atovaquone-proguanil 
hydrochloride combination for malaria treatment appears to satisfy most of these 
conditions as detailed below.
ATOVAQUONE: This is one of a series of synthetic hydroxynaphthoquinones found to 
have potent activity against Pneumocystis carinii, Toxoplasma gondii and 
Plasmodium falciparum. It is active against the erythrocytic stages of plasmodium 
development and the early gametocyte stage. It has a novel mechanism of action 
by depolarising parasitic mitochondria and inhibiting the electron transport system 
at the level of cytochrome bci complex. In malaria parasites, there is obligatory 
coupling of pyrimidine biosynthesis and electron transport via ubiquinone/ubiquinol
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2123. The selective toxicity of atovaquone towards Plasmodium falciparum is 
achieved by virtue of the different sensitivities of mammalian and plasmodial 
electron transport systems to hydroxynaphthoquinones, and also by the fact that 
plasmodium species are dependent on de novo pyrimidine biosynthesis, while 
mammalian cells are able to salvage and recycle pyrimidines. The inability of 
malaria parasites to salvage preformed pyrimidines, results in atovaquone blocking 
nucleic acid synthesis, and thus replication, in plasmodial cells 21'23.
Pharmacokinetically however, atovaquone is characterised by relatively poor 
bioavailability. The oral bio-availabity is approximately 23%, which can be 
increased by 3 to 6 fold when taken together with a fatty meal. It is further 
characterised by low steady-state plasma concentration and high plasma protein 
binding. Excretion is almost exclusively through faeces with no significant hepatic 
metabolism or renal excretion. The half-life ranges from 50 to 70 hours. In a 
pharmacokinetics studies in malaria patients,the Cmax, which is an important 
determinant of therapeutic outcome was 2.8hours and mean half-life 31.8hours26"29.
The drug is currently used as monotherapy for the treatment of Pneumocystis 
carinii pneumonia.
It should be noted that no other antimalarial has atovaquones’ mechanism of action 
and this may explain the low incidence of its resistance worldwide and makes it a 
suitable candidate for drug combinations 25 26 27.
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proguanil: It is a biguanide derivative, first synthesised and assessed initially for 
the treatment of acute Plasmodium vivax malaria. Since then it has been used in 
prophylaxis, initially as a single agent and lately in combination with chloroquine, 
and has proved to be extremely well tolerated alone and in combination. It is 
metabolised in vivo principally by P- 450 iso-enzyme 2C19 to cycloguanil, an active 
metabolite, which is a potent inhibitor of dihydrofolic acid reductase.
Proguanil and cycloguanil are active against erythrocytic and extraerythrocytic 
stages of plasmodium development and are described as slow blood schizonticidal 
agents. Proguanil is well absorbed, achieving Cmax within 2 to 5 hours.
It is metabolised in the liver to the dihydrofolate reductase inhibitor, cycloguanil. 
The transformation to cycloguanil is very rapid. The cycloguanil Cmax occurs one 
hour after the Cmax of Proguanil. The metabolism of proguanil is mediated by 
CYP3A4 and CYP2C19 isoenzymes. The later is a potential site for drug 
interaction.
There is considerable genetic polymorphysim of this CYP enzyme, with up to 20% 
‘poor metabolisers’ in Asian and African populations. Poor metabolisers have very 
low or undetectable plasma concentrations of cycloguanil. The polymorphism may 
be a cause of failure in prophylaxis in poor metabolisers.
The half-life of proguanil is 12 to 20 hours in patients with malaria and healthy 
volunteers but longer in poor metabolisers. The half-life of cycloguanil is 
approximately 12 hours. Proguanil is safe and synergistic toxicities have not 
observed when proguanil was combined with other antimalarials hence its current 
combination with atovaquone 26-31.
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ATOVAQUONE PLUS PROGUANIL COMBINATION: Atovaquone and Proguanil
hydrochloride has been developed as a fixed drug combination of the two 
antimalarial agents by Glaxo Wellcome (Malorone™) and has been approved in the 
United States by federal drug administration for oral prophylaxis and the treatment 
of malaria due to Plasmodium falciparum, including resistant strains 30 31 32.
The rationale for combining these 2 types of folate synthesis inhibitors is however 
due to their synergistic activity and the fact that different genes express their 
resistance, which reduces the chance of selection of resistant strains.
Though resistance to some folate inhibitors has developed in most endemic areas 
of the world, the degree of this resistance differs markedly. Atovaquone and 
Proguanil work to interfere with 2 different pathways involved in the biosynthesis of 
pyrimidines in the malarial parasites. In the plasmodia, atovaquone selectively 
inhibits mitochodrial electron transport, reduces pyrimidine biosynthesis, collapsing 
mitochodrial membrane potential thereby preventing parasite replication.
Cycloguanil, the active metabolite of proguanil, inhibits dihydrofolate reductase, 
leading to depletion of pyrimidine nucleotide pools and disruption in nucleic acid 
synthesis and cell replication 26 29"32.
In addition atovaquone and proguanil act synergistically against the erythrocytic 
stages of the parasite. Though the mechanism of this synergistic activity has not 
been precisely determined, in vitro studies suggest that the proguanil-specific 
synergistic effect with atovaquone is not so much dependent on its active 
metabolite, cycloguanil, but rather on its own specific biguanide effect. It is 
explained that proguanil, rather than cycloguanil, lowers the concentration of
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atovaquone needed to collapse mitochondrial membrane potential in malarial 
parasites.
This is an advantage in that the combination will still be effective in cycloguanil 
resistance and also genetic polymorphism for the CYP2CIP isoenzyme or its 
inhibition by other drugs would not affect their efficacy 22 26 33.
Pharmacokinetics: The combined administration of atovaquone and proguanil does 
not change the pharmacokinetics of either drug. Atovaquone absorption from the 
gastrointestinal tract remains poor but increases with a fatty meal. The drug is still 
excreted mostly unchanged in faeces with an elimination half-life of 2 to 3 days, but 
low plasma levels may persist for several weeks. While proguanil is rapidly 
absorbed from the gastrointestinal tract, reaching peak plasma levels in 2 to 4 
hours, it is concentrated in erythrocytes, metabolised in the liver by CYP2C19 and 
excreted in urine with half-life of 12 to 21 hours 26,29,30,34-
Uses: Atovaquone and proguanil hydrochloride is used in adults and children 
weighing 11 kilogram or more for chemoprophylaxis of malaria caused by 
Plasmodium falciparum and for the treatment of acute, uncomplicated malaria 
caused by Plasmodium falciparum. It is however noted that more evidence is 
needed on either drugs’ activity against Plasmodium vivax hypnozoites. Neither 
atovaquone nor proguanil is active against hypnozoites, so the combination can 
neither cure nor prevent delayed primary attacks or relapse of P. ovale or P. vivax 
malaria. However it is the drug of choice for presumptive self-treatment of travellers 
to areas where resistance has been reported.
The recommended adult dosage for the treatment of uncomplicated attacks of 
malaria caused by Plasmodium falciparum is one gram of atovaquone and four
12
hundred milligrams of proguanil hydrochloride once daily for 3 consecutive days. 
Alternatively, adults may receive 500 mg of atovaquone and 200 mg of proguanil 
hydrochloride every 12 hours.
Children weighing 11-20 kg may receive 250 mg of atovaquone and 100 mg of 
proguanil hydrochloride once daily for three consecutive days: those weighing 21 - 
30 kg receive 500 mg atovaquone and 200 mg proguanil, children 31-40 kg receive 
750 mg atovaquone and 300 mg of proguanil hydrochloride. Children weighing 
more than 40 kg may receive the usual adult dosage. Alternatively, children may 
receive half the recommended total daily dosage every 12 hours for three days 30,31
Adverse effects: Atovaquone plus proguanil is well tolerated; abdominal pain, 
nausea, vomiting, diarrhoea, headache and rash have occurred and are common 
with the higher doses used for treatment.
Elevations of liver enzymes have occurred but vary substantially in clinical studies 
of malaria therapy. In most patients, the enzyme levels returned to normal during 
follow-up. One treatment-related death and one case of anaphylaxis have been 
reported to date. 30,31,32
Pregnancy: Proguanil alone is studied and considered safe for use in pregnancy 
but the safety of atovaquone and the combination is as yet unknown 30,31.
Drug Interactions: Drugs affecting the hepatic microsomal enzymes that are 
inhibitors of substances of the cytochrome P-450 (CYP) isoenzyme are potential 
pharmacokinetic interactors because they can alter proguanil metabolism. However 
to date no known proguanil drug interactions have been reported. Co-administration 
of metoclopramide with atovaquone decreases atovaquone bioavailability. It should 
be used concomitantly only if other antiemetics are not available.
13
Rifampicin has pharmacokinetic interactions with atovaquone and reduces plasma 
concentration of atovaquone by about 40% to 50%. Concomitant administration is 
therefore not recommended. Also tetracyclines have pharmacokinetic interactions 
with atovaquone and decrease plasma atovaquone concentration. If concomitantly 
used then parasitaemia should be closely monitored 26 30,31 32
Clinical Trials: Many pivotal clinical studies have compared atovaquone plus 
proguanil to other drugs for the treatment of Plasmodium falciparum malaria. In 
three of such studies atovaquone/proguanil treatment led to higher cure rates than 
mefloquine (100% versus 86%)35, amodiaquine (98% versus 81 %)36 and another 
chloroquine with pyrimethamine/sulfadoxine (100% versus 88%)37. In yet another 
three studies, atovaquone/proguanil was as effective as quinine plus tetracycline 
(98% versus 100%)38, pyrimethamine/sufadoxine (100% versus 98.8%)39 or 
halofantrine (93.8% versus 90.4%)40.
Also the efficacy of atovaquone/proguanil has been evaluated for 
chemoprophylaxis in other studies. In two randomised double-blind trials involving 
semi-immune adults living in endemic areas. It was found that the drug is able to 
prevent malaria in 98% to 100% of those taking atovaquone/proguanil compared to 
48% to 63% of patients treated with placebo 4142. A similar study in semi-immune 
children found atovaquone/proguanil 100% effective compared to 82% with 
placebo43. In addition, randomised trials in non-immune travellers have found the 
combination as effective as mefloquine as well as chloroquine plus proguanil 44 
However, in such randomised studies without placebo the degree of exposure to 
malaria infection becomes unclear and such results may not be generalisable.
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From the above and in all of its reported clinical studies and development, the 
combination has had excellent safety profiles. Most of the adverse experiences that 
have occurred so far have been those associated with the high doses used and 
they are always typical of malaria signs and symptoms and resolved within follow­
up periods. These excellent clinical results and pharmacokinetic qualities of 
atovaquone and proguanil combination have demonstrated that the combination is 
equally and sometimes more effective and safe than the existing antimalarials.
However in almost all of these studies, the sample sizes have been small; therefore 
making their estimates and confidence intervals very wide and thus lacking 
precision and power.
There was therefore a need for a systematic review and re-synthesis of the 
available evidence that atovaquone plus proguanil is a novel combination for 
malaria treatment to produce more confident and precise estimates.
This study therefore qualitatively and quantitatively reviewed, and pooled the 
existing data on the efficacy and safety of the atovaquone plus proguanil 
combination for the treatment of Plasmodium falciparuom malaria using the World 
Health Organisation day 28 in vivo efficacy testing guidelines. The main objectives 
were to determine more precise estimates of the clinical and parasitological cure 
rates, the mean fever and parasite clearance times, the incidence and frequency of 
adverse effects and to assess the compliance to treatment and losses to follow-up.
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2.0 METHODS AND MATERIALS:
The methods employed in the study involved systematic literature review and 
meta-analysis of selected pre-existing published articles. These methods as 
outlined below and in the subsequent paragraphs in this research report were 
based on the modified versions of the methods described for use in epidemiology 
by authors in this field 46 52
2.1 STUDY DESIGN, SITES AND POPULATION:
DESIGN: The design involved an in-depth qualitative and quantitative review using 
structured guidelines and meta-analysis of results of the pre-existing independent 
published studies on atovaquone-proguanil combination and a comparator drug for 
the treatment of acute Plasmodium falciparum malaria. The pre-existing studies 
were such that all adult patients were randomly assigned to receive either 
atovaquone thousand milligrams per day total dose co-administered with proguanil 
four hundred milligram per day total dose for three days or the comparator drug for 
its standard regimen and duration. Children were dosed according to their body 
weight, with a target dose of 20 mg/kg atovaquone and 8-mg/kg proguanil. They 
must have all been followed up for 28 days. Primary efficacy was determined by 
day 28 cure rate using the World Health Organisation in vivo testing guidelines. 
Secondary efficacies were based on parasite and fever clearance times. Also 
incidence and frequencies of adverse experiences were determined using those 
that were passively reported by participants and also from clinically significant 
laboratory results from routinely collected study specimens.
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SITES AND SETTING: Studies were selected from all malaria endemic sites across
the world. However only five studies from five multiple sites qualified for inclusion. 
Three were in Africa (Gabon, Zambia and Kenya) 36,39,4°, one in Southeast Asia 
(Thailand)35 and the other in South America (Brazil)38.
They consisted of five comparative clinical efficacy studies of acute Plasmodium 
falciparum malaria, using treatment regimen of atovaquone plus proguanil 
combination and different comparator drugs. All the selected studies or trials were 
open-label, randomised clinical trials reported during the last ten years.
p o p u l a t io n : The study population consisted of the participants in the selected 
studies. These consisted of female and male patients, children and adults between 
the ages of 3 and 65 years. They were all diagnosed as having acute Plasmodium 
falciparum malaria that was confirmed by both clinical and parasitological 
evidence. Only the five pivotal clinical trials / studies undertaken from 1993 to 1996 
and which fully met all the selection criteria were included in the final meta­
analysis.
2.2 DATA SEARCH, SELECTION AND EXTRACTION
d a ta  s e a r c h  s t r a t e g y : The search strategy employed was to first conduct a 
formal computerised literature (Medline®) search for published articles using the 
following key words: malaria, atovaquone, proguanil, atovaquone-proguanil, 
malarone and combination treatment. These key references were then examined 
for additional relevant references, and the process continued until no further new 
published articles were obtained. To minimise the shortcomings of this method, 
efforts were made to distinguish between independent studies and those repeated 
several times in the literature. Also literature from other databases(such as Pub
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med and cochrane library), local journals, unpublished results and those from 
negative association or results that were not indexed were vigorously sought for by 
electronic mail communication with experts in the field and by ordering some 
through the school library to avoid publication bias. Only articles in English were 
used, as the literature search did not find any article in other languages.
STUDY selection CRITERIA: Studies were included if they met all of the following 
criteria:
(a) . Randomised controlled trial
(b) . Study was on acute Plasmodium falciparum malaria.
(c) . Atovaquone-proguanil had been compared to another antimalarial drug.
(d) . Malaria case diagnosis included parasitological confirmation.
(e) . The results contained information on participants’ demographic characteristics.
(f) . The study had measured the day 28 safety and efficacy of atovaquone- 
proguanil in participants as a primary outcome measure.
(g) . The study had information on parasite and fever clearance times.
(h) . There was information on adverse effects or experience.
(i) . There was information on the treatment schedules and follow-ups.
(j) . There was the existence of full published or unpublished report.
data extraction: For each of the selected articles the following details were 
extracted and tabulated; the site of the study, the period of the study, the study 
population, the participants’ basic demographic characteristics (age and sex), the 
sample size and the response rate, as well as the treatment doses and schedules, 
the comparative drugs, the follow-up period, outcome variables and efficacy
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statistics. In addition, information on loss to follow-up and clinical and laboratory 
adverse effects were extracted.
Two independent experienced persons did the extraction using a pre-designed 
table and guidelines under the facilitation of the author and the direction of his 
research report supervisors.
s a m p l in g . The final five selected articles for this research report were all pooled 
and included as part of the overall sample size estimation.
For a study with dichotomous outcome (cured or not cured) and based on the 
overall cure rates at day 28 as a primary efficacy outcome. The sample size 
estimation was determined as follows. Previous estimates of cure rates for 
atovaquone-proguanil combination were over ninety percent in most cases. Thus 
assuming 85% cure rate and the probability of 95% that the estimated parameter 
will be within 5% of the true value, the minimum number of participants or cases 
required from the pooled articles was 196. This was calculated using Epi-lnfo 
software. However, assuming 20% loss to follow-up, and for the purposes of non 
intention-to-treat analysis the total minimum pooled cases required were 236.
2.3 DATA MANAGEMENT:
Only results from the five selected studies were included in the final data 
management and re-synthesis. All the essential information needed was initially 
used in the literature review and then extracted, tabulated and pooled. They were 
then re-synthesised into one measurement. Qualitative and quantitative methods 
were used in all stages of data management. For the qualitative assessment the 
independent reviewers applied the checklist and the scoring to finally select the five 
articles. However for the quantitative analysis, all the reported estimates were
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extracted and based on the studies objectives the essential data was pooled and 
later resynthesied.
q u a lit a t iv e  a s s e s s m e n t : Reports of all the retrieved literature were reviewed and 
qualitatively assessed using a review checklist system as detailed figure 1.
They were later sent to independent reviewers for final review and scoring 
according to their quality. Below is the checklist and scoring system used.
The Qualitative Checklist and Scoring System used:
(a) . Clearly stated objectives; yes or no (1,0)
(b) . Study design; randomised, placebo-controlled, blinding. (1 each)
(c) . Defined accessible population; yes or no (1,0)
(d) . Subject demographic characteristics stated; yes or no (1,0)
(e) . Subject selection; probabilistic, consecutive, others (3, 2,1 respectively)
(f) . Sample size adequacy; yes or no (1, 0)
(g) . Response rate; > 75 % or less (1,0)
(h) . Malaria case diagnosis; appropriate or inappropriate (1,0)
(i) . Adequate treatment procedures; yes or no (1,0)
(j) . Sufficient follow-up: yes or no (1,0)
(k) . Outcome variables; appropriate or inappropriate (1,0)
(l) . Unethical issues; yes or no (1,0)
(m) . Systematic error; none, minimal, moderate and severe (4,3,2,0)
(n) . Appropriate statistical test; yes or no (1,0)
(o) . Adequate data analysis; yes or no (1,0)
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(p). Adequate level of statistical precision; yes or no (1,0)
(q). Consistent reporting: yes or no (1,0)
QUANTITATIVE ASSESSMENT: This involved extracting all numerical values including 
the point and interval estimates of the selected articles. These include the period of 
study, number of males and females, the age range, mean age and its standard 
deviation, the mean weight with its standard deviation and the geometric mean and 
range of parasite counts. In addition treatment doses, duration and follow-up were 
also extracted. Also the number, which completed 28 days follow-up, the number 
cured, the cure rates, the fever and parasite clearance times were noted.
Further, total withdrawals, loss to follow-up and the frequency of adverse effects 
were recorded. The extracted data was tabulated and resynthesised. Rows were 
created for each quantitative variable and separate columns were allocated for 
each of the selected articles or studies.
STATISTICAL ANALYSIS: This involved all the data with summary measures for the 
separate and pooled results. Since the studies were all estimating day 28 cure 
rates and their sample sizes were comparable, the homogeneity assumption was 
made and the fixed effect model used47 by pooling their standard deviations using 
the formula SDP= V{(ni-1)SDi2 +(n2-1)SD22 +,..+ (nx-1)SDx2 }/( ni+n2 +,..+nx )53. 
Hence weighted averages were estimated for the entire reported estimates and 
their confidence constructed after estimating the pooled standard deviation and 
error using the pooled formula 53.
The pooled average-weighted estimates and confidence intervals for the mean age, 
weight and parasite counts and their ranges were all determined using stata 
statistical software and presented.
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For the treatment outcomes graphical methods of display using all the clinical 
outcomes were estimated for the individual and the combined results.
The raw data were also combined and reanalysed. The 95% confidence intervals 
for the combined results were portrayed. Overall statistical significance/ pooled 
measures of effects estimated were used for comparing comparator drugs.
Since the compliance of a treatment regimen mirrors its acceptability and hence 
final effectiveness in the field, a null hypothesis of no difference between efficacy 
and effectiveness were tested to see if there was a clinically significant difference 
between the two cure rates.
All the results were later discussed and inferences drawn. In addition, the 
limitations of the study were stated. References were also compiled and presented.
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3.0 RESULTS:
The report results are grouped under three major headings: qualitative extractions, 
quantitative extractions and finally the study outcomes and endpoints.
3.1 THE QUALITATIVE EXTRACTIONS
Steps employed in selecting the final 5 articles for the meta-analysis 
FIGURE 1: Flow diagram of steps used to select the final articles.
1These articles were rejected because atovaquone or proguanil was just 
mentioned in their write-up and not studies involving of atovaquone/proguanil.
2 These articles had studied and reported on atovaquone/proguanil but the studies 
were not clinical efficacy studies
3 Ten of these articles could not meet the initial study selection criteria as detailed 
in the next page and one article from Peru did not arrive.
4 These two articles did not meet the minimum required qualitative score of 18.
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The table below gives the background information of the 5 final selected articles.
TABLE l: The Study number, site and source of the final five selected articles.
# Site Authors, title and Source of the journal articles selected
1 Kenya Anabwani G, et al. Combination atovaquone and proguanil 
versus halofantrine for treatment of acute Plasmodium 
falciparum malaria in children. Paediatric Infectious Diseases 
Journal. 1999; 18:456-61.
2 Zambia Mulenga M, et al. Atovaquone and proguanil versus 
pyrimethamine/sulfadoxine for the treatment of acute 
Plasmodium falciparum in Zambia. Clinical Therapeutics. 
1999;21 (5):841 -52.
3 Gabon Radloff PD, et al. Atovaquone and proguanil for Plasmodium 
falciparum malaria. Lancet. 1996; 347:1511-14.
4 Brazil De Alencar FEC, et al. Atovaquone and proguanil for the 
treatment of malaria in Brazil. The Journal of Infectious 
Diseases. 1997; 175:1544-7.
5 Thailand Looareesuwan S, et al. Efficacy and safety of 
atovaquone/proguanil compared with mefloquine for the 
treatment of Plasmodium falciparum malaria in Thailand. 
American Journal of Tropical Medicine and Hygiene. 1999; 
60(4): 526-532.
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Below is the independent reviewers report on the qualitative results of the 5 final 
articles:
TABLE II: The Final Qualitative Scores (Score range: 19-21).
Criteria for qualitative assessment (score)
Study number 1 2 3 4 5
Clearly stated objectives; yes or no (1,0) 1 1 1 1 1
Design; randomised/ placebo-controlled/ blinding. (1 each) 2 1 2 1 2
Defined accessible population; yes or no (1,0) 1 1 1 1 1
Basic demographic characteristics stated; yes or no (1,0) 1 1 1 1 1
Subject selection; probabilistic, consecutive or other non- 
probabilistic (3, 2,1 respectively)
2 2 2 2 2
Sample size estimation stated; yes or no (1,0) 0 0 1 0 0
Follow-up rate;> 75 % , < less (1,0) 1 1 1 1 1
Malaria case diagnosis; appropriate or inappropriate (1,0) 1 1 1 1 1
Adequate treatment procedures; yes or no (1,0) 1 1 1 1 1
Sufficient 28 day follow-ups: yes or no (1,0) 1 1 1 1 1
Outcome variables; appropriate or inappropriate (1,0) 1 1 1 1 1
Serious unethical issues; yes or no (0,1) 1 1 1 1 1
Bias; none, minimal, moderate and severe (4,3,2,0) 3 3 3 3 3
Appropriate statistical test; yes or no (1,0) 1 1 1 1 1
Adequate data analysis; yes or no (1,0) 1 1 1 1 1
Adequate level of statistical precision; yes or no (1,0) 1 1 1 1 1
Consistent reporting: yes or no (1,0) 1 1 1 1 1
Total score 20 19 21 19 20
25
3.2. THE QUANTITATIVE EXTRACTIONS
TABLE III: The Quantitative Extractions Results:
Selected Study number 1 2 3 4 5
Selected Study site Kenya Zambia Gabon Brazil Thailand
Selected Study period 1994-1994 1993 -1994 1994 -995 1996-1996 1993- 1994
Sample size 84 82 71 88 91
# Females 45 2 37 0 20
# Males 39 80 34 88 71
Age range in years 3-12 14-49 15-65 18-65 17-65
Mean age (years) (SD) 6.4 (2.7) 25.9 (7.8) 32(17) 30.2(9.7) 27.9(10.3)
Mean weight (kg) (SD) 18.1 (5.2) 56.3 (7.2) 59(11) . . . 52.9(8.5)
Parasite geometric mean /ul 29 686 14,799 5030 12,059 38,270
Parasite range 738-
364,928
872-61,813 225-
100,000
(SE 1696) 570-
198,800
Total dose (mg) (A:P) (20:8)mg/kg* 1000: 400 1000:400 1000:400 1000:400
Treatment duration/days 3 3 3 3 3
Follow-up period in days 28 28 28 28 28
# of 28-day follow-up 81 80 63 77 79
# of patients cured 76 80 62 76 79
Cure rate in % 93.8 100 87** 98.7 100
# of patients withdrawn 3 2 0 8 1
# loss to follow-up 0 0 8 3 11
Mean Fever clearance time, 
hours (SD)
35.9 (28.3) 30.4 (28.2) 16(22) 18.8(17.7) 58.9(36.1)
Mean Parasite clearance time, 
hours (SD)
64.9(17.3) 64.0(21.7) 72(23) 56.1(14.1) 65.2(17.6)
Compactor drug H a lo fa n tr in e P y r im e th a m in e  
- s u lfa d o x in e
A m o d ia q u in e Q u in in e  + 
te tra c y c lin e
M e flo q u in e
* Dose per kilogram body weight for children.
** Cure rate by intention-to-treat analysis
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3.3 THE BACKGROUND INFORMATION:
In all, the results from five clinical trials from three continents Africa (3/5), Asia 
(1/5) and South America (1/5) were pooled. The percentage of participants from 
each of the five contributing sites were Kenya 20.1% (84/416), Zambia 19.7% 
(82/416), Gabon 17.1% (71/416), Brazil 21.2% (88/416) and Thailand 21.9 
(91/416). All were undertaken between the periods 1990 to 2000 and had 
compared atovaquone plus proguanil to halofantrine, sufadoxine/pyrimethamine, 
amodiaquine, quinine plus tetracycline and mefloquine respectively. They were 
reviewed by two independent persons and satisfied all inclusion/exclusion criteria.
TABLE IV: The Site, Number and Percent Contribution to overall Sample Size.
Study Site Study Number Sample Size Percent Total
KENYA 1 84 20.2
ZAMBIA 2 82 19.7
GABON 3 71 17.1
BRAZIL 4 88 21.1
THAILAND 5 91 21.9
Combined (6) 416 100
FIGURE 2: Pie Chart of Percent Sample Size Per Site
5 1
17%
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POOLED PATIENTS CHARACTERISTICS: A total of 416 participants with acute 
uncomplicated Plasmodium falciparum malaria randomised to treatment with 
atovaquone plus proguanil only are analysed.
In all 75% (312/416; 95% Cl 70.5, 79.1) of the total cases were males.
About 20% (84/416; 95% Cl 16.4, 24.3) were between the ages of 3 to 12 years. 
The weighted-average estimate of the mean age was 24.4 years. ( 95% Cl 23.4, 
25.4; the pooled SD =10.3). The combined age, ranged from 3 to 65 years old.
Also the weighted average estimate of the mean weights was 46.2 kilograms 
(95% Cl 45.4,47.0; the pooled SD = 8.1).
The minimum geometric mean of Plasmodium falciparum parasite count reported 
by the studies was 5030 per microliter and the maximum was 38,270 per 
microliter. However, the overall range was between 225 to 364,928 parasites per 
microliter.
The treatment regimens were all the same; for adults’ one-gram atovaquone and 
400-milligram proguanil were given together as single daily doses for three 
consecutive days.
However children were dosed according to their body weight, with a target dose of 
20mg/kg atovaquone and 8-mg/kg proguanil.
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3.4 THE PRIMARY EFFICACY ENDPOINTS:
t r e a t m e n t  OUTCOMES: The follow-up period for which treatment outcomes were 
measured was 28 days. Of the total 416-pooled patients in the study, 380 fully 
completed treatment and finished the 28 days follow-up, making the overall study 
response rate of about 91% (380/416; 95% Cl 88.2, 93.7).
Fourteen of the patients, about 3.4 % (14 / 416), were withdrawn for various 
reasons before study completion while another 22 patients about 5.3% (22 / 416) 
were lost to follow-up.
Table V below gives further details of the results in terms of total sample size per 
study, number completed, cured and withdrawn, and the cure rates by evaluable 
patients and by intention to treat analysis.
ta b le  v: Treatment Outcomes, Cure Rates and Confidence Intervals
Study # Sample Number Number Number
Cured
95% Cl of Cure rates
Site
size Completed Withdrawn Evaluable subjects Intention-to-treat
Kenya 1 84 81 3 76 93.8(86.1,98.0) 90.5(82.0,95.8)
Zambia 2 82 80 2 80 100(95.5,100) 97.6(91.4,99.7)
Gabon 3 71 63 8 62 98.4(91.4,99.9) 87.3 (77.3,94.0)
Brazil 4 88 77 11 76 98.7(92.9,99.9) 86.4(77.3,92.7)
Thailand 5 91 79 12 79 100(95.4,100) 86.8(78.1,92.9)
Combined 6 416 380 36 373 98.2 (96.2, 99.3) 89.7(86.3,92.4)
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CURE RATES BY EVALUABLE PATIENTS (EFFICACY):
Using the WHO in vivo day 28 efficacy testing guideline. A total of 380-pooled 
patients completed the study treatment and the 28-day follow-up and were thus 
evaluable for efficacy analysis. Out of this number, 373 were cured of their malaria 
without recrudescence in the 28 days follow-up. This gives the treatment cure rate 
(efficacy) of atovaquone plus proguanil in the study population to be 98.2% 
(373 / 380; 95% Cl 96.2%, 99.3%).
ta b le  v  presents the precise 95% confidence intervals of the individual and 
combined results and figure 3 below gives the graphical presentation.
fig u r e  3: 95% Cl of Cure Rates by Evaluable Patients (Efficacy)
95%CI Study# 1 2 3 4 5 6
100
95
90
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CURE RATES BY INTENTION-TO-TREAT ANALYSIS (EFFECTIVENESS):
Intention to treat analysis to determine the effectiveness of the pooled results was 
also done. That is, all the randomised participants were included in the final 
analysis. Out of the total 416 participants initially randomised 373 were cured. This 
gives the estimated effectiveness of atovaquone plus proguanil in the combined 
study population to be 89.7% (373/416; 95% Cl 86.3% to 92.4%). TABLE V: above 
and Figure 4: below depict details of the 95% confidence intervals of the individual 
and the combined results.
FIGURE 4: 95% Cl of Cure Rates by Intention-to-Treat Analysis (Effectiveness)
95CI% Study # 1 2 3 4 5 6
100
95
90
85
80
75
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CURE RATES: EFFICACY VERSUS EFFECTIVENESS.
Since the compliance of a treatment regimen mirrors its acceptability and hence 
the final effectiveness in the field, I compare below the treatment efficacy to the 
effectiveness. I then tested the null hypothesis that there is no significant 
difference between the combined study treatment efficacy (373/380) and treatment 
effectiveness (373/416).
The results of a binomial exact test is significantly as follows:
95% Cl for the difference = 5.3% to 11.7% (p < 0.0001).
The results of the efficacy and effectiveness of the individual and combined results 
are depicted by a bar chart; FIGURE 5 and the confidence intervals of the difference 
in the two cure rates are depicted on tab le  VI and fig u r e  6 in the next page:
FIGURE 5: The Comparison of the Study Efficacy and Effectiveness
Study Number
□ efficacy □ effectiveness
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TABLE VI: Differences between the treatment Efficacy and Effectiveness
Site # Total size #Completed # Withdrawn #Cured 95% Cl of the difference
Kenya 1 84 81 3 76 -11.5,4.83
Zambia 2 82 80 2 80 -5.7, 0.9
Gabon 3 71 63 8 62 -19.4, -2.8
Brazil 4 88 77 11 76 -19.9, -4.7
Thailand 5 91 79 12 79 -20.1, -6.2
Combined 6 416 380 36 373 -11.7, -5.3
fig u r e  6 : 95%CI Differences Between Treatment Efficacy and Effectiveness
95%CI Study # 1 2 3 4 5 6
16
12
08
-20
From the above; studies 1 and 2 showed no significant difference between efficacy 
and effectiveness. While in studies 3, 4 and 5 there were significant differences. 
Also, the combined (study 6) result showed a significant difference and more 
precise estimate with a between the two cure rates (5.3% to 11.7% p < 0.0001)).
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3.5 THE SECONDARY EFFICACY ENDPOINTS:
THE FEVER CLEARANCE TIMES:
The weighted-average mean fever clearance time was 32.8 hours (95% Cl 30.1 to 
35.4). (Pooled SD= 27.4 hours). The range of the reported mean fever clearance 
times was 16.0 to 58.9 hours. Below are details on TABLE Vll and figure 8.
ta b le  Vll: Fever Clearance Times and Confidence Intervals
Study
Number
Sample
Size
Mean Fever 
Clearance Time
Standard 
Deviation (SD)
95% Confidence Interval
1 84 35.9 28.3 (29.7, 42.1)
2 82 30.4 28.2 (24.2, 36.5)
3 71 16.0 22.0 (10.7, 21.2)
4 ~88 18.8 17.7 (15.0, 22.5)
5 91 58.9 36.1 (51.3, 66.4)
6(combined) 416 32.8 27.4 (30.1, 35.4)
FIGURE 7: 95% Confidence Intervals of Fever Clearance Times 
95% Cl Study # 1 2 3 4 5 6
69 
60
45
I
3
34
THE PARASITE CLEARANCE TIMES:
The weighted-average mean parasite clearance time was 64.1 hours (95% Cl 62.3 
to 65.9). The range was 56.1 to 72.0 hours, table viii and figure 8 gives further 
details.
TABLE vill: Parasite Clearance Times and Confidence Intervals
Study
Number
Sample
Size
Mean Parasite 
Clearance Time
Standard 
Deviation (SD)
95% Confidence Interval
1 84 64.9 17.3 61.1, 68.6
2 82 64.0 21.7 I59.2 68.7
3 71 72.0 23.0 66.5, 77.4
4 88 56.1 14.1 53.1, 59.0
5 91 65.2 17.6 61.5, 68.8
6(combined) 416 64.1 18.8 62.2, 65.9
FIGURE 8: 95% Cl of parasite clearance times:
95%CI Study # 1 2  3 4
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WITHDRAWALS:
In all 14 (3.4%) participants were withdrawn from the studies before the stipulated 28 
days follow-up. The reasons for withdrawal were as follows: two participant were 
removed for withdrawal of parental consent, one was removed for repeatedly vomiting of 
the study drug, six were detected to have taken other antimalariais during the follow-up 
period and five were found to have developed concomitant infections.
LOSSES TO FOLLOW-UP:
In all 22 study participants, 5.3% (22/416) were lost to follow-up from the study 
before the end their 28 days follow-up.
3.6 SAFETY ANALYSIS:
SYMPTOMATIC SAFETY ANALYSIS:
Reported adverse experience analysis is restricted to data on participants that 
were reported by the selected studies. In all 397 out of the total 417 participants 
were reported to have complained of one or more adverse experiences. The 
reported adverse experiences were typical of malaria symptoms. In descending 
order of frequency, the 10 most common adverse experiences were abdominal 
pain 16.9% (67/397), vomiting 13.6% (57/397), and headache12.1% (48/397), 
diarrhoea and nausea were the same 9.8% (39/397). The rest were weakness 
7.3% (29/397), pruritus 5.5% (22/397), anorexia and dizziness were the same 
4.8% (19/397) and last but not the least coughing 2.5% (10/397). TABLE IX on the 
next page illustrates the detail frequencies.
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TABLE IX: Reported symptomatic adverse effects; results of the selected studies
Study number 1 2 3 4 5 Total 100%
Sample size 84 82 63 77 91 397 100.0
Vomiting 13 10 18 4 9 54 13.6
Nausea 6 21 12 39 9.8
Diarrhoea 4 13 12 5 5 39 9.8
Pruritus 9 4 3 6 22 5.5
Headache 8 23 17 48 12.1
Abdominal Pain 8 23 14 20 2 67 16.9
Dizziness 6 3 10 19 4.8
Anorexia 3 6 5 5 19 4.8
Weakness 1 19 9 29 7.3
Coughing 10 10 2.5
Insomnia 2 5 7 1.8
Rash 3 3 0.8
Chills 2 2 0.5
Epistaxis 1 1 0.3
Myalgia 8 8 2.0
Palpitation 1 3 4 1.0
Hepatomegaly 5 5 1.3
Hypotension 6 6 1.5
Splenomegaly 3 3 0.8
Tinnitus 3 3 6 1.5
Sore throat 7 7 1.8
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LABORATORY SAFETY ANALYSIS:
Only two of the selected studies (numbers 2 and 5) reported on clinically 
significant laboratory abnormalities. However all were the types commonly seen in 
malaria infections. In most of the patients the laboratory abnormalities resolved 
after treatment and before the end of the day 28 follow-ups. The six most 
significant ones in decreasing frequency were, increased eosinophil counts 27.8% 
(48/173), decreased neutrophil count and increased aminotransferase were the 
same at 10.4% (18/173). The rest were decreased albumin 9.8% (17/173), 
increased aspartate aminotransferase 8.7% (15/173) and decreased red blood cell 
count 5.9% (9/173). Refer to TABLE X below for further details
ta b le  X: Clinically Significant Laboratory Abnormalities.
Laboratory test Criteria Study number 2 (n=82) Study 5 (n=91) Combined
Developing
abnormality
Abnormal 
at day 28
Developing
abnormality
Abnormal 
at day 28
n=173(%)
Haematocrit <25% 1 0 6 0 7 (4.1)
Haemoglobin <7.5g/dl 0 0 4 0 4 (2.3)
Red blood cell <3x1012/L 1 0 8 0 9 (5.2)
White blood cell <3x109/L 2 0 3 0 5( 2.9)
Neutrophil count <1x109/L 14 4 4 0 18(10.4)
Eosinophil > 1000/piL 10 8 38 32 48(27.8)
Platelet count <50x109/L 3 0 3 (1.7)
Creatinine >2.0mg/dl 2 0 0 0 2 (1.2)
Albumin <3.0g/dl 11 4 6 0 17(9.8)
Bilirubin >2.0mg/dl 6 0 6 (3.5)
ALT >100u/L 3 1 15 2 18(10.4)
AST >100u/L 3 0 12 3 15(8.7)
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4.0 DISCUSSION:
Early diagnosis and prompt treatment of malaria with effective drugs has been the 
cornerstone of malaria control, especially in endemic areas where for economic 
and other reasons, other measures of control are absent or inadequate. However 
the rapid development and spread of malaria parasite resistance to existing 
antimalarials is posing increasing threats to this control strategy. The situation is 
even more serious, not only because new efficacious drugs are expensive and 
slow in development but also because these drugs must be easy to use, have few 
adverse effects and be deployed in such ways as combination therapy so as to 
protect and prolong their useful lifespan. From the systematic review, qualitative 
and quantitative analysis so far, it has been shown in this research report that not 
only is atovaquone plus proguanil a novel combination but also it fulfils most of the 
criteria of combination, high efficacy, easy administration and fewer and 
acceptable adverse effects.
This combination is better than mefloquine plus artesunate and sulfadoxine- 
pyrimethamine plus artesunate combinations in terms of its synergistic activity 33 
and relatively shorter terminal half-life, which is a selective pressure for drug 
resistance and invariably determines the useful lifespan of a given drug.
Regarding novel structures the mechanism of action of atovaquone by 
depolarising parasitic mitochondria and selectively inhibiting the electron transport 
system at the level of cytochrome bci complex is unique 21. Couple to this, is the 
proguanil specific synergistic effect with atovaquone, which is not so much 
dependent on its active metabolite, cycloguanil, but rather on its own specific 
biguanide effect. This is a significant advantage that will make the combination still
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effective even in the context of cycloguanil resistance. Again the genetic 
polymorphism for the CYP2CIP isoenzyme or its inhibition by other drugs would 
not affect their efficacy due to this synergism 26.
On efficacy of atovaquone-proguanil, the results of this study confirm what had 
been previously reported. With treatment efficacy rate of 98.2% (95% Cl 96.2%, 
99.3%) atovaquone-proguanil has higher cure rates than current mono-therapies 
like mefloquine and amodiaquine, and halofantrine, which had previously been 
thought to be similar, although the background parasite resistance rates were not 
described for the various study sites. Also atovaquone-proguanil is equally 
efficacious to current frontline combinations like artesunate plus pyrimethamine / 
sulfadoxine, artesunate plus mefloquine and quinine plus tetracycline but higher 
than pyrimethamine /sulfadoxine plus chloroquine or amodiaqiune in the areas 
where the comparative studies were done 35 36 37 38 39 40
Also to assess the combinations acceptability and compliance in the field, 
intention-to-treat analysis was done and then compared to cure rates due to 
evaluable cases only. The atovaquone-proguanil is highly effective with an 
intention-to-treat cure rate of 89.7% (95% Cl 86.3% to 92.4%). Though the results 
from a binomial exact test {95% Cl 5.3% to 11.7%, p-value < 0.0001} indicates 
that the effectiveness is significantly different from the efficacy (98.2%). Though 
this is a significant finding its implication on the usefulness of the drug is minimal 
as most of the reasons for the withdrawals and hence the difference between the 
combination’s efficacy and effectiveness were mainly drug unrelated: two 
participant were removed for withdrawal of parental consent, one was removed for 
repeatedly vomiting of the study drug, six were detected to have taken other
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antimalarials during the follow-up period and five were found to have developed 
concomitant infections.
the combination is still more effective than most current mono-therapies in 
endemic areas and is comparable to other drug combinations if intention to treat 
analysis were to be estimated.
The study has also been able to obtain and improve on estimates of the treatment 
outcomes by pooling the five studies. The study treatment efficacy of 98.2% (95% 
Cl 96.2%, 99.3%) and effectiveness of 89.7% (95% Cl 86.3% to 92.4%) is the 
most precise estimates compared to any individual results ever published. This is 
shown on tables V and VI and depicted graphically on figure 3 and 4. In all cases 
the confidence estimates were reduced. However I am unable to determine the 
precise estimates for women and children separately as not all the retrieved 
articles provided separate data on women and children.
On the side of the secondary efficacy parameters, the results showed that patients 
treated with atovaquone-proguanil have mean fever clearance times of 32.8 hours 
(95% Cl 30.1 to 35.4). This finding is significantly shorter than fever clearance time 
reported in sulfadoxime-pyrimethamine, halofantrine , and mefloquine . Also the 
mean atovaquone-proguanil fever clearance time was comparable to that of 
chloroquine plus sulfadoxime-pyrimethamine 35'37'39'40.
Once again these comparative results may not be valid in areas that differ from the 
study areas with regard to background parasite resistance patterns. However this 
finding is relatively higher and converse compared to quinine plus tratracycline as
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previously reported38. Again this finding is significantly higher than in amodiaquine 
alone and in combination with sulfadoxime-pyrimethamine.
Further patients treated with atovaquone proguanil have mean parasite clearance 
time of 64.1 hours (95% Cl 62.3, 65.9) which is significantly shorter than that of 
amodiaquine and mefloquine35 36. However this finding is comparable to quinine 
plus tetracycline38 initial thought to shorter and other combinations. However the 
combination has a higher parasite clearance time than sulfadoxime/pyrimethamine 
, chloroquine or their combination and halofantrine 394°. Parameters of fever and 
parasite clearance times are important, as they are suggestive of the rate of drug 
effect. Also delayed parasite clearance time in addition to shallow concentration 
effect of drugs due to long terminal half life is a strong determinant of resistant 
parasite selection especially in areas where malaria re-infections are common.
It is stressed that the weighted-average estimates are appropriate and are used in 
the statistical analysis because the study outcomes are the same justifying the 
homogeneity assumption and hence the invoking of the fixed effect model.
Also by pooling the various studies we have been able to improve on the 
precisions of the individual estimates and thus further enhance outcomes
Furthermore the difficulty in drug combination and safety were assessed. While it 
may appear simple to combine antimalarials for use, the procedure is often limited 
by drug interactions, which may alter the absorption, distribution, elimination, toxic 
levels or effectiveness of the individual or the combined agents. From the results 
of our systematic review, the combined administration of atovaquone and 
proguanil does not change the pharmacokinetics of either drug and also 
synergistic toxicities were not observed. This is so because proguanil has no
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known drug interactions when combined with other antimalarials and hence its 
combination with atovaquone 26.
Atovaquone and proguanil were both well tolerated. Though 397 out of the total 
417 participants complained of one or more adverse experience, all of them were 
typical of malaria symptoms. The three most common adverse experiences were 
abdominal pain, vomiting and headache. Others were diarrhoea, nausea, 
weakness, pruritus, anorexia and dizziness. The percentage of abdominal pains is 
16.9 (95% Cl 13.3.20.9) smaller than found in halofantrine,
sulfadoxine/pyrimethamine and quinine plus tetracycline whilst higher than found 
in amodiaquine and mefloquine. The higher frequency of abdominal pain can 
however be attributed to the number of tablets patients have to swallow.
Also about 14% (95%CI 11,18) complained of vomiting which is higher than that 
found in mefloquine and halofantrine but similar in sufadoxine/pyrimethamine and 
amodiaquine and smaller in quinine plus tetracycline. Again about 12% (95%CI 
9,16) reported of headache, this is similar in halofantrine and quinine plus 
tetracycline but smaller in mefloquine 35 36 37 38 3940 These and the other findings 
are however related to malaria treatment and do not point to any specific toxicity. 
Two of the selected studies also reported on significant laboratory abnormalities, 
the results showed that significantly 27.7% had raised eosinophils, however this is 
attributed to the high prevalence of helminthic infections in the areas of study.
Also about 10% had raised liver enzymes and raised neutrophil counts while about 
9% had decreased albumin. All did not differ much from the comparable drugs, 
and all resolved except the eosinophils within the follow-up period.
In all they were not clinically symptomatic.
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To determine effectiveness, the adequacy of response rate in the studies was 
assessed. In all about 91.3% achieved the study primary endpoint. However about 
3.4% (14/416) participants were withdrawn before the stipulated follow-up. The 
reasons for withdrawal were as follows: two participant were removed for 
withdrawal of parental consent, one was removed for repeatedly vomiting of the 
study drug, six were detected to have taken other antimalarials during the follow­
up period and five were found to have developed concomitant infections.
Also 22 study participants, 5.3% (22/416) were lost from the study before the end 
their 28 days follow-up. The above findings suggest that atovaquone-proguanil 
combination is very safe and acceptable. This is because though the intention to 
treat analysis showed a significant difference of effectiveness from the efficacy, 
the reasons were not directly related to the combination.
This notwithstanding, however the tolerability of atovaquone and proguanil 
combination in terms of gastrointestinal side effects requires further clarification in 
studies in which a fixed dose combination tablet is administered. Reduction in 
dosage form may hold further benefits and this may have to be looked into in 
future evaluation and studies.
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5.0 CONCLUSION
The re-emergence of malaria and the progressive antimalarial drug resistance 
represent threats to inhabitants of malaria endemic areas. These underscore the 
need for new and effective strategies for the multi-drug resistant malaria, although 
no such satisfactory strategy has yet been established. Indications are that the 
emergence of drug resistance can be slowed or prevented altogether by use of 
combinations of antimalarials with different modes of action. However like any 
other solution there are also difficulties and limitations. The immediate ones are 
drug toxicities due to interactions, optimum regimen and end product cost. While 
no single drug may be able to satisfy all these conditions, atovaquone-proguanil 
with novel structures can be said to have many of these qualities. Result from this 
study has shown that this combination is novel with excellent cure rate and safety 
profile for use in malaria treatment. Also to date recrudescence parasitaemia after 
treatment with atovaquone-proguanil appears to be rare and resistance has not 
been an issue in individual patients so far treated with atovaquone-proguanil. This 
notwithstanding however, widespread use of any antimalarial drug will eventually 
increase the risk that resistance may occur and spread. Atovaquone-proguanil is 
also potentially susceptible to rapid development of resistance if deployed alone, 
due to its relatively long parasite clearance time and the relatively long half-life of 
atovaquone. There will therefore be the need to combine this fixed dose 
combination with another anti-malarial drug, preferably an artemisinin derivative, so 
as to prolong its use and life span. Also, at its current price, the cost of 
atovaquone-proguanil treatment is very high compared to other similar efficacious 
drugs. It might therefore be necessary to reserve atovaquone-proguanil as a 
second or third line drug in malaria therapy in endemic areas for patients who fail
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treatment with the existing drugs. In fact, this will be in line with the drug 
manufacturers’ donation program with the task force for child survival and 
development, to make this highly effective but expensive drug available for to those 
who need most but are least able to afford it.
This study had used meta-analysis in order to improve the precision of estimates 
of efficacy and effectiveness, since published studies thus far have suffered from 
small sample sizes. However there are limitations to the techniques used. It must 
be stated that whilst every effort was made to vigorously search, select and 
include all studies on atovaquone plus proguanil for malaria treatment, some data 
might not have been indexed, leading to publication bias. Also it was not possible 
to acquire the raw data and published literature had to be used. These findings 
have demonstrated good efficacy, novel mechanism of action, synergistic activity 
against malaria parasites and favourable adverse effects of the two drugs in 
patients with Plasmodium falciparum malaria. It can be concluded that the above 
results provide substantial evidence that the atovaquone plus proguanil is safe and 
effective for Plasmodium falciparum malaria treatment. The atovaquone proguanil 
combination is therefore an important new alternative for Plasmodium falciparum 
malaria and should serve as an important therapeutic option in areas of the world 
where malaria drug resistance is a problem.
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